两性霉素B
荟萃分析
医学
不利影响
系统回顾
肾毒性
寒冷
随机对照试验
两性霉素B脱氧胆酸盐
药理学
内科学
抗真菌
梅德林
生物
皮肤病科
毒性
生物化学
卡斯波芬金
作者
Laiza Maria Steimbach,Fernanda S. Tonin,Suzane Virtuoso,Helena Hiemisch Lobo Borba,Andréia Cristina Conegero Sanches,Astrid Wiens,Fernando Fernández-Llimós,Roberto Pontarolo
出处
期刊:Mycoses
[Wiley]
日期:2016-11-22
卷期号:60 (3): 146-154
被引量:78
摘要
Summary Invasive fungal infections, an important cause of mortality, are primarily treated using amphotericin B, which is available in different formulations, both conventional and lipid‐based (liposomal, lipid complex, colloidal dispersion and Intralipid ® infusion). The aim of our study was to determine the efficacy and safety of conventional amphotericin B vs its lipid‐based formulations. A systematic review followed by pairwise meta‐analysis was performed, including randomised controlled trials ( RCT s) that evaluated the use of lipid‐based amphotericin B in patients with any degree of immunosuppression and susceptibility to invasive fungal infection. An electronic search was conducted using PubMed, Scopus, Web of Science and Scielo databases. Extracted outcomes were related to efficacy (cure) and safety (incidence of adverse events). Results were evaluated and meta‐analyses were performed. Twenty‐three RCT s were identified (n=2677 participants) for meta‐analysis. No significant differences between conventional amphotericin B and any of the five formulations evaluated were observed, with regard to the efficacy analysis. With respect to the adverse events of nephrotoxicity, fever, chills and vomiting, all lipid formulations presented better profiles than the conventional formulation. The present systematic review and meta‐analysis showed that conventional amphotericin B presents the same efficacy profile as lipid‐based formulations, although the latter were associated with a safer profile.
科研通智能强力驱动
Strongly Powered by AbleSci AI